Not Clearly Pro or Con to the question "Should Marijuana Be a Medical Option?"
"Otsuka's scientists consider cannabinoids to be a significant potential source of new medicines, and as world leading pioneers in this field, GW represents the ideal partner for Otsuka. Otsuka is committed to maximizing the potential of Sativex in the US market and looks forward to exploring a range of longer term cannabinoid product opportunities."
Taro Iwamoto, PhD, President & COO, Otsuka Pharmaceutical Development & Commercialization, Inc., in a Press Release with GW Pharmaceuticals regarding their collaboration in the marketing of the Cannabinoid-based drug Sativex to U.S. Markets (accessed Feb. 14, 2007)
Organizations/VIPs/Others Individuals and organizations that do not fit into the other star categories.
"Founded in 1964, Otsuka Pharmaceutical Co., Ltd....researches, develops, manufactures and markets innovative, original products, focusing its core businesses on pharmaceutical products for the treatment of disease and consumer products for the maintenance of everyday health. Otsuka and its consolidated subsidiaries earned US $6.8 billion in consolidated annual revenues in fiscal 2005. The Group has R&D facilities in Japan (Osaka and Tokushima), EU (Frankfurt) and US (Rockville, MD). Its commercial operations are headquartered in US (Rockville, MD and Princeton, NJ), EU (UK) and Japan (Tokyo)."
"Otsuka - People creating new products for better health worldwide. This phrase embodies the following three principles:
Creating innovative products through our own ingenuity
Supporting human health and well-being
Contributing to people around the world
When Otsuka Pharmaceutical Co., Ltd. initiated original drug development efforts in 1971, the above phrase was adopted as the guiding philosophy for research and development. The phrase was later adopted as our corporate philosophy, governing all activities undertaken by our company in pursuit of our goals."